Skip to content
Search

Latest Stories

Pharmacists to get 'Acon Flowflex' new LFD test kits for Covid-19

Community pharmacy contractors ordering lateral flow device (LFD) test kits will receive a different brand of test kits (Acon Flowflex) from Alliance Healthcare, once the existing stock of the Innova test kits has been distributed.

"When the new stock is received, the Innova test kits should continue to be supplied to patients in the first instance to use up the pharmacy’s existing stock," the Pharmaceutical Services Negotiating Committee (PSNC) said.


A carton (outer) of the Acon FlowFlex test kits will contain 56 test kits and the carton dimensions are 36 x 38.5 x 44cm.

The main differences to note as well as the pack size, are that the Acon Flowflex test kits: are nasal swab only; and provide a test result within 15 minutes instead of 30 minutes – the test should not be left to develop for longer than 30 minutes as this will void the test and will need to be repeated.

It is therefore important for pharmacists to continue to advise patients to follow the instructions on how to use the tests kits contained within the box.

The changes in pack size will not affect the weekly reporting requirement for stock received as contractors are required to report the quantity of cartons (outers) received, not the number of test kits (as well as the lot number, supplying wholesale and date of receipt).

Contractors can continue to use the same PIP code (8943995) to order LFD tests for the time being. As new LFD products are introduced, if there is a subsequent change in the PIP code, PNSC will communicate this to contractors.

 

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less